A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Inclusion Criteria: * Age \>/= 18 years at time of signing informed consent form (ICF) * Ability to understand and the willingness to sign a written informed consent document * Patients with histologically confirmed advanced thymoma or thymic carcinoma * Patients who have experienced disease progression after treatment with at least one prior systemic therapy * Measurable disease per RECIST v1.1 * Availability of pre-treatment tumor tissue (archival or fresh); If archival tissue is not available and a fresh biopsy is not considered safe and medically feasible by the Investigator, the patient may be approved for enrollment after consultation with the Principal Investigator * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment: * Absolute neutrophil count (ANC) \>/= 1.5 x 10\^9/L (1500/uL) without filgrastim support * Platelet count \>/= 100 x 10\^9/L (100,000/uL) without transfusion * Hemoglobin (Hgb) \>/= 80 g/L (8 g/dL). Patients may be transfused to meet this criterion. * Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) \</= 2.5 x upper limit of normal (ULN), with the following exceptions: * Patients with documented liver metastases: AST and ALT \</= 5 x ULN * Patients with documented liver or bone metastases: ALP \</= 5 x ULN Serum bilirubin \</= 1.5 …